Cytarabine
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | DEPOCYT | — | 2007-04-19 | fda.gov ↗ |
| Approved | EU (EMA) | DepoCyte | — | 2001-07-11 | europa.eu ↗ |
| Approved | US (FDA) | CYTARABINE | — | 1969-06-17 | fda.gov ↗ |
Trials 702 · started per year
Also used as a comparator or background therapy in 778 trials
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-02-28 | AbbVie | AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML) abbvie.com ↗ |
Evidence & citations 55 cited values
Every value below carries the sentence it was read from. 1,488 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cytarabine | “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗1355“An alternative approach comprised of a shorter induction treatment with rituximab, HD-MTX and cytarabine (MARTA) followed by age-adjusted high-dose chemotherapy and autologous...” NCT06830421 ↗ “One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine,...” NCT06861244 ↗ “Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8,...” NCT06211452 ↗ “In a protocol of treatment of AML used in 1994 for adults with AML up to the age of 50 years, the Spanish CETLAM group showed a complete remission rate 75 % using the...” NCT01716793 ↗ “Standard Chemotherapy includes IA(Idarubicin combined with Cytarabine) or DA(Daunorubicin combined with Cytarabine). IDA is given by venous drip daily at 12mg/m2, or DNR is...” NCT06810791 ↗ “To determine the safety, tolerability and recommended phase II dose (RP2D) of Revumenib incombination with cytarabine and daunorubicin and Gemtuzumab ozogamicin (GO) in...” NCT07052994 ↗ “The goal of this clinical research study is to learn if clofarabine, when given in combination with ara-C (cytarabine), can help to improve the disease's response to therapy...” NCT00065143 ↗ “R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion...” NCT02657785 ↗ “SENTI-202 is administered in either a 3 dose regimen (Schedule 1: Days 0, 7, 14) or a 5 dose regimen (Schedule 2: Days 0, 3, 7, 10, 14) of a 28-day treatment cycle following a...” NCT06325748 ↗ “R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in...” NCT02836158 ↗ “Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide,...” NCT00554164 ↗ “BACKGROUND: The combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested to be safe and effective for adult acute promyelocytic leukaemia...” PMID 29615003 ↗ Apr 2018 “The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy...” NCT02099292 ↗ “Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning...” PMID 39134959 ↗ Aug 2024 “This is an interventional, multicenter, open label, phase II study designed to evaluate the safety and efficacy of Clofarabine in combination with low dose Cytarabine in...” NCT01302106 ↗ “cytarabine (dose level 1, 200 mg/m2 continuous intravenous infusion on days 4-10; dose level 2, cytarabine 500 mg/m2 intravenously twice a day on days 3-5; or dose level 3,...” PMID 41791831 ↗ Mar 2026 “This has also been the basis for successful application and granting of Orphan-Drug designation for cytarabine (Ara-C) liposome injection (trade name: DepoCyt) for the...” NCT01044966 ↗ “Participants will receive standard low-intensity therapy (LIT) regimens for newly diagnosed AML, which may include venetoclax combined with either azacitidine, decitabine, or...” NCT07014462 ↗ “Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1;...” NCT06176027 ↗ “R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered...” NCT01865110 ↗ “DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2...” NCT01014208 ↗ “R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate...” NCT01854372 ↗ “Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin,...” NCT01290120 ↗ “R-ESHAP:rituximab 375mg/m\^2 Day 1, etoposide 40mg/m\^2/day IV on Days 1-4, methylprednisolone 500mg/day IV on Days 1-4 or 5, cisplatin at 25mg/m\^2/day CI Days 1-4, cytarabine...” NCT03391466 ↗ “Cytarabine is given at a dose of 100 mg/m2 intravenous infusion over a 1 hour period, every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem...” NCT00058292 ↗ “Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per...” NCT02042391 ↗ “A Phase I-II Study of a Liposomal Formulation of Cytarabine and Daunorubicin (CPX-351) in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing...” NCT04109690 ↗ “CPX-351 is a formulation of two drugs, cytarabine and daunorubicin, that is administered as the first part of treatment to get rid of as many leukemia cells in your bone marrow...” NCT04209725 ↗ “Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm,...” PMID 32873343 ↗ Sep 2020 “Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine.” NCT04501614 ↗ “ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.” NCT05992597 ↗ “Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)” NCT00392990 ↗ “Low-dose cytarabine (LoDAC); azacytidine; homoharringtonine (HHT), cytarabine and aclarubicin (HAA) or fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG)” NCT04716114 ↗ “High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).” NCT02920008 ↗ “Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5.” NCT01278602 ↗ “Cytarabine 500 mg/m\^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.” NCT00472849 ↗ “2 cycles of cytarabine in average (Ig/m2 in Group 2) and standard (100 mg/mi2 in Group 1) doses in combination with idarubicin (8-12 mg/m2) and mitoxantrone (10 mg/m2)” PMID 25314773 ↗ 2014 “Multi-agent chemotherapy including vincristine, prednisone, daunorubicin, cyclophosphamide, pegaspargase, cytarabine, 6-MP, MTX, and dexamethasone per protocol phases.” NCT07454226 ↗ “The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.” NCT01018069 ↗ “Treatment consisted of three 21-day cycles of BV 1.8 mg/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin 100mg/m2; day 1 and cytarabine 2x2g/m2; day 2).” PMID 32273476 ↗ Apr 2021 “MATRix Regimen: Rituximab 375 mg/m² IV on Day 0; Methotrexate 3.5 g/m² IV on Day 1; Cytarabine 2 g/m² IV twice daily on Days 2-3; Thiotepa 30 mg/m² orally on Day 4.” NCT07350850 ↗ “Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin.” NCT04342936 ↗ “Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation” NCT05870995 ↗ “Lumbar puncture: cytarabine 50mg+dexamethasone 5mg+methotrexate 10mg, intrathecal injection, once a month after remission, a total of 4-6 courses of treatment.” NCT06861348 ↗ “* EA±Mitox regimen: etoposide injection 100 mg/m2, cytarabine injection 100-150 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).” NCT06387069 ↗ “Cytarabine, Subcutaneous injection, 10 - 100mg per square meter, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).” NCT06537843 ↗ “Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine” NCT03319901 ↗ “Includes vincristine, daunorubicin, cyclophosphamide, pegaspargase, prednisone, dexamethasone, cytarabine, 6-mercaptopurine, and high-dose methotrexate.” NCT07495631 ↗ “Cytarabine (AraC) is a commercially available chemotherapy drug that is active against leukemia and used routinely when the disease is first diagnosed.” NCT00655395 ↗ “DA regimen: daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle.” NCT05939180 ↗ “CPX-351 is made up of two chemotherapy drugs that patients may have already received called cytarabine and daunorubicin that are now packaged together.” NCT01943682 ↗ “intermediate-dose cytarabine regimen ： 3 courses If IDH1 mutant residual disease was positive before consolidation chemotherapy, Ivosidenib was added;” NCT06611839 ↗ “Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course.” NCT01987297 ↗ “Subjects on Low-Dose Cytarabine (LoDAC) received 10 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10\~14 days.” NCT05586074 ↗ “Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2” NCT00594555 ↗ “Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide” NCT02766868 ↗ “Mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine will be used as conditioning regimen for ASCT in the lymphoma patients.” NCT05681403 ↗ “High-Dose Cytarabine (HiDAC): 3.0 g/m², intravenously (iv), over 3 hours, every 12 hours (q12h) on Days 1, 3, and 5 (total of 6 doses per cycle)” NCT07259707 ↗ “Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran” NCT00574509 ↗ “Course A: Cyclophosphamide days 1, 2 and 3. Vincristine days 4 and 11, Doxorubicin day 4, dexamethasone days 1-4 and 11-14, Cytarabine day 7.” NCT05581030 ↗ “A Phase 1b/2a Clinical Study of CWP232291 in Combination With Cytarabine in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)” NCT03055286 ↗ “Patients will receive 30 mg/m2 per day intravenously of fludarabine for 5 days and 2000 mg/m2 per day intravenously of cytarabine for 5 days.” NCT03446638 ↗ “AraC (Cytarabine) 1-2 g/m², administered intravenously every 12 hours on days 1-3, may be combined with anthracycline/anthraquinone agents.” NCT07425782 ↗ “Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)” NCT02323022 ↗ “Cytarabine is designed to insert itself into DNA (the genetic material of cells) of cancer cells and stop the DNA from repairing itself.” NCT00778375 ↗ “Cytarabine 500 mg/m2/day continuous infusion over 24h from D1 to D3 followed by cytarabine 2-hour bolus of 1000 mg/m2/12h from D8 to D10” NCT01455025 ↗ “Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.” NCT03512197 ↗ “ADE chemotherapy Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days” NCT03053206 ↗ “A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma” NCT02416206 ↗ “Cytarabine, 2 mg/m\^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2” NCT00955916 ↗ “Induction therapy included idarubicin 8 mg/m2 on days 1 to 5, cytarabine 100 mg/m2 on days 1 to 7, and lomustine 200 mg/m2 on day 1.” PMID 28129526 ↗ Oct 2016 “Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).” NCT01690065 ↗ “cytarabine (4 g/m2/day, days -10 to -9 (for unrelated donors or haploidentical donors; and 4 g/m2/day, days -9 for sibling donors))” NCT04582604 ↗ “A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia” NCT07423104 ↗ “Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).” NCT06578247 ↗ “Bugitinib orally once daily, Venetoclax orally once daily with dose escalation to target dose, and Cytarabine intravenously daily.” NCT07563179 ↗ “In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.” NCT01828489 ↗ “Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.” NCT06226571 ↗ “Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) injection for 10 days.” NCT05876832 ↗ “First consolidation course: daunorubicin 45 mg/m2 x 1 (iv infusion) day 1-3 and cytarabine 1000 mg/m2 x 2 (iv infusion) day 1-4.” NCT01794169 ↗ “with clofarabine (30 mg/m2 /d, Days 1-5), cytarabine (750 mg/m2 /d, Days 1-5), and mitoxantrone (12 mg/m2 /d, Days 3-5) (CLAM).” PMID 32187883 ↗ Mar 2020 “However, median duration of aplasia was significantly prolonged in comparison to that of the AI (cytarabine, idarubicin)-block.” NCT00111345 ↗ “The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.” NCT05667402 ↗ “Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))” NCT01653067 ↗ “Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia” NCT00944008 ↗ “Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme).” NCT02519712 ↗ “The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7.” NCT01496547 ↗ “Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d” NCT04880746 ↗ “Participants will receive an intensive chemotherapy regimen of cytarabine and daunorubicin by intravenous (IV) infusion.” NCT07211958 ↗ “Hyper-CVAD-A: Cyclophosphamide ,Vincristine , Doxorubicin , Dexamethasone ; Hyper-CVAD-B: Methotrexate , Cytarabine .” NCT07564453 ↗ “Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin).” NCT06841952 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05740449 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT07175415 ↗ “granulocyte colony-stimulating factor (G-CSF) combined with low-dose cytarabine (Ara-C) and aclacinomycin (ACR)” NCT04168138 ↗ “3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.” NCT02340936 ↗ “Patients without CNS involvement will receive one dose of Liposomal cytarabine for CNS prophylaxis on day -13.” NCT02393157 ↗ “The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3.” NCT02665143 ↗ “Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase” NCT03236857 ↗ “semustine 250mg/m2 PO d1; etoposide 200mg/m2 IV d2-5; cytarabine 400mg/m2 IV d2-5; melphalan 140mg/m2 IV d6.” NCT05504603 ↗ “Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.” NCT05657639 ↗ “chemotherapy consisting of Cladribine (5mg/m2), cytarabine (1.5g/m2) and mitoxantrone （10mg/m2）for 5 days” NCT02910752 ↗ “intensive chemotherapy(cytarabine with idarubicin or daunorubicin), which short as"7+3 induction regimen"” NCT06746519 ↗ “Cytarabine is designed to insert itself into DNA of cancer cells and stop the DNA from repairing itself.” NCT01025154 ↗ “cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion” NCT01417767 ↗ “Cytarabine 100mg/m² days 1-7 Idarubicin 12mg/m² days 1-3 Avapritinib orally on days 8-21 (28-day cycle)” NCT07028073 ↗ “Day -10# Cytarabine 4g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid;” NCT05075681 ↗ “2-Chlorodeoxyadenosine (2-CdA) and Cytarabine (Ara-C) in Idiopathic Hypereosinophilic Syndrome (HES)” NCT00483067 ↗ “Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine” NCT00875667 ↗ “Initial Cytoreduction is performed with DHAP- protocol using dexamethasone, cytarabine and cisplatin” NCT00384553 ↗ “Rituximab 2 x 375 mg/m2, HD-Methotrexate 3.5 g/m2, HD-Cytarabine 2 x 2 g/m2, Thiotepa 30 mg/m2; i.v.” NCT04931368 ↗ “;Cytarabine (Cytarabine): 100mg/m2 on days 1 to 7; intravenous infusion or subcutaneous injection.” NCT06232694 ↗ “replacing the intrathecal methotrexate to intrathecal cytarabine, methotrexate and hydrocortisone.” NCT02339350 ↗ “cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.” NCT01453205 ↗ “cytarabine 100-200 mg/m\^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days” NCT01074047 ↗ “Intermediate dose Cytarabine (IDAC) schedule Cytosine Arabinoside 1g/m2 daily by 4 hour infusion” NCT02272478 ↗ “Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan” NCT03882203 ↗ “Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab” NCT01046825 ↗ “BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab” NCT01468311 ↗ “HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3” NCT05274139 ↗ “Cytarabine: 100 mg/m\^2 IV days 1 to 7, to begin 4 hours after the administration of GO.” NCT01698879 ↗ “cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.” NCT05578378 ↗ “Cytarabine(Ara-C) is another agent which is commonly used for intrathecal chemotherapy.” NCT03082144 ↗ “ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5” NCT00909168 ↗ “Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP).” NCT04179929 ↗ “Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP).” NCT07443592 ↗ “Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7)” NCT04628026 ↗ “induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day” NCT00943553 ↗ “subcutaneous injection of cytarabine 20 mg twice daily on days 1-10 of 28-day cycles” PMID 31175001 ↗ Jun 2019 “Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37” NCT02451774 ↗ “Cytarabine at 100 mg/m² on study days 1-7 as a continuous infusion over 22-24 hours” NCT05829434 ↗ “Cytarabine: 18-60yrs: 3g/m² bid / \>-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3” NCT03989713 ↗ “BeEAC (Bendamustine, Cytarabine, Etoposide, Cyclophosphamide) conditioning regimen” NCT03315520 ↗ “Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles” NCT02374424 ↗ “NOVE-HiDAC consists of mitoxantrone, etoposide, and modified high-dose cytarabine.” NCT01222143 ↗ “All patients will receive 70 mg of intrathecal cytarabine on day "0" of course 1.” NCT01321346 ↗ “DepoCyt is a new slow-release form of the cancer drug called ara-C (cytarabine).” NCT00029523 ↗ “Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia” NCT01794702 ↗ “Cytarabine (ARAC): 60 mg / m 2 iV in 1 hour 16 to 19, 23 to 26. (8 total doses).” NCT01366898 ↗ “2 to 4 cycles of IV P-DHAP (pembrolizumab, dexamethasone, cytarabine, cisplatin)” NCT04838652 ↗ “salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP)” NCT00003143 ↗ “RTC preconditioning regimen consisted of cytarabine (2g/m2/day, days -10 to -9)” NCT07677306 ↗ “cytarabine( Ara-C) 1500mg/m2(\<60 year old) ; 1000mg/m2(\>60 year old) IV q12h” NCT03453255 ↗ “Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2” NCT03187210 ↗ “Early induction intensification with cladribine, cytarabine, and mitoxantrone” PMID 31661339 ↗ Oct 2019 “During Cycles 1 and 2, participants will receive fludarabine and cytarabine.” NCT05326516 ↗ “consisting of cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9” NCT03793517 ↗ “cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2” NCT06652165 ↗ “High-dose cytarabine 1 - 3 g/m2 (days 1-3)/Mitoxantrone 20 mg/m2 (days3-5)” NCT02461537 ↗ “Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;” NCT04881838 ↗ “treated with high-doses of methotrexate and cytarabine, followed by R-HDS” PMID 26282634 ↗ Aug 2015 “polatuzumab vedotin x 1; methotrexate x 1; rituximab x 1; cytarabine x 5;” NCT05253495 ↗ “IT cytarabine given intrathecally to all patients on day 1 of each cycle” NCT01324180 ↗ “Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7.” NCT00927498 ↗ “Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days” NCT00474006 ↗ “Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine” NCT00774332 ↗ “Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution” NCT01827605 ↗ “Cytarabine 2000mg/m2 (1000mg/m2 for patients aged over 65) iv.drip d2,3” NCT04624958 ↗ “Cytarabine (Ara-c) 100mg/㎡/day, days 3-7 (given as a 24-hour infusion)” NCT05893472 ↗ “high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.” NCT01960192 ↗ “Etoposide 200 mg/m2 and Cytarabine 400 mg/m2 for 4 days (D-6 to D-3)” NCT02008006 ↗ “Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5” NCT00932412 ↗ “Cytarabine is routinely used in the treatment of patients with AML.” NCT01147939 ↗ “Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine.” NCT04230239 ↗ “Cytarabine: 2,000 mg/m\^2 IV over 4 hours, on Days 1, 2, 3, 4, 5.” NCT02356159 ↗ “Drug: Cytarabine 2 g/m\^2 by vein on Days -6, -5, -4, -3, and -2.” NCT02809092 ↗ “Drug: Cytarabine 1 g/m2 intravenously for 5 days in the 2nd week” NCT05807659 ↗ “ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin)” NCT00568815 ↗ “cytarabine - 2 g/m\^2 q12 hrs (2 doses) on day 2 of dosing cycle” NCT00823719 ↗ “Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5” NCT00520130 ↗ “cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2” NCT02278796 ↗ “Cytarabine (A): 3000 mg/m2 IV over 3 hours on Day 1 and Day 2” NCT01858922 ↗ “cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9” NCT03799224 ↗ “methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)” NCT00466258 ↗ “PD-1 inhibitor+venetoclax+Cytarabine+Aclarubicin+G-CSF regimen” NCT07541755 ↗ “cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days” NCT02172872 ↗ “Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3” NCT01805557 ↗ “Cytarabine (Ara-C): 1 g/m² IV q12h (Days 2-3; total 4 doses).” NCT07059156 ↗ “cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17” NCT03985007 ↗ “Cytarabine: (Ara-c 100mg/㎡/d, day 1-4; 1g/㎡ /q12h, day 5-7)” NCT06529250 ↗ “VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)” NCT01083342 ↗ “cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16” NCT05029141 ↗ “Chidemide，carmustine, etoposide, cytarabine, and melphalan” NCT05931263 ↗ “Cytarabine: 75 mg/m2 iv on days 35-38, 42-45, 49-52, 56-59” NCT02396043 ↗ “cytarabine 10 mg/m2 every 12 hours, subcutaneous injection” NCT05982756 ↗ “Cytarabine (75 mg/m2/day, intravenously, bolus injection.” NCT03390387 ↗ “Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7;” NCT05662956 ↗ “Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7” NCT05807347 ↗ “Cytarabine: 10mg/m2, every 12 hours, IV drip, days 4-10” NCT06651866 ↗ “Cytarabine 10mg/(m2.d) by SC on days 1-7 of every cycle” NCT04722952 ↗ “2. Cytarabine (75-100 mg/m2 every 12 hrs, days 1 to 5).” NCT07512700 ↗ “Etoposide, dexamethasone, cytarabine, cisplatin (EDAP)” NCT00580372 ↗ “Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim” NCT00893399 ↗ “Cytarabine: 2 g/m² intravenously once daily on day -1.” NCT07583888 ↗ “Cytarabine:10mg/m2,q12h,d4\~10, subcutaneous injection” NCT06394011 ↗ “ID-AraC: Intermediate-dose cytarabine in cycle 5,7,9.” NCT07493161 ↗ “cytarabine 2000 mg/m2 every 4 weeks until progression” NCT01626664 ↗ “Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection” NCT04087967 ↗ “Drug :SKLB1028 ;Drug: Cytarabine ;Drug: Daunorubicin” NCT05445154 ↗ “Cytarabine 200 mg/m2 IV continuous infusion days 1-7” NCT02084563 ↗ “Cytarabine 10mg/m2 subcutaneous injection q12h d1-14” NCT06470841 ↗ “Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.” NCT02140606 ↗ “rituximab + dexamethasone + cytarabine + cisplatin” NCT02055924 ↗ “Intravenous Cytarabine: 100 mg/m²/day on days 1-7” NCT07108530 ↗ “low-dose cytarabine (ara-C) and aclarubicin (ACR)” NCT05382390 ↗ “Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)” NCT00844298 ↗ “Daunorubicin/ Cytarabine or Idarubicin/Cytarabine” NCT04676243 ↗ “20 mg cytarabine administered subcutaneously (SC)” NCT02348489 ↗ “Cytarabine 100 mg/m2 twice a day (Days -5 to -2)” NCT00329030 ↗ “200 mg/m\^2 cytarabine cont inf i.v. on days 1-7” NCT05904106 ↗ “Clofarabine Crizotinib Cytarabine HCl Dabrafenib” NCT02551718 ↗ “Regimen B :IVAC:ifosfamide,etoposide，cytarabine.” NCT03558412 ↗ “Cytarabine 400mg/m2 intravenous infusion, day2-5” NCT06682130 ↗ “Cytarabine 20 mg SC every 12 hours on Days 1-10” NCT07172204 ↗ “Cytarabine 2 x 200 mg/m², iv, day -6 to day -3” NCT00946374 ↗ “Part B: high dose methotrexate and cytarabine.” NCT07294677 ↗ “low-dose cytarabine (10 mg/m2 q12 h, days 3-9)” NCT05258799 ↗ “cytarabine 100mg/m2 BID on days -5 through -2” NCT00572013 ↗ “BEAM (BCNU, Etoposide, Cytarabine, Melphalan)” NCT02858258 ↗ “intrathecal liposomal cytarabine (DepoCyte®)” NCT00854867 ↗ “Cytarabine-based consolidation chemotherapy” NCT02927938 ↗ “cytarabine 1000 mg/m2 over 3 h on days 2-4” NCT03392714 ↗ “Daunorubicin 8.8mg/m2 + cytarabine 20mg/m2” NCT04990102 ↗ “Cytarabine \* (ARA-C) 1-2g/m2 q12H D2-3 iv” NCT05347641 ↗ “Cytarabine administered at 500 mg/m²/day.” NCT07617285 ↗ “Cytarabine 100 mg/m2/day IV 1 h 4, 5 days” NCT02842931 ↗ “Cytarabine: 200mg/m2/d ivgtt q12h D-6-D-3” NCT05367856 ↗ “Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4” NCT06652139 ↗ “Cytarabine 150 mg/m2/day IV 1 h 4, 5 days” NCT03479918 ↗ “cytarabine (Ara-C) (4 g/m2/day, days -9)” NCT06984536 ↗ “Methotrexate/Cytarabine/Prednisone i.th.” NCT01953770 ↗ “cytarabine + daunorubicin induction, 7+3” NCT04988555 ↗ “Depocyt (Cytarabine Liposome Injection)” NCT00199108 ↗ “methotrexate/hydrocortisone/cytarabine” NCT03515200 ↗ “BCNU, Etoposide, Cytarabine, Melphalan” NCT03113162 ↗ “* Fludarabin * Cytarabine * Venetoclax” NCT04000698 ↗ “methotrexate/hydrocortisone/cytarabine” NCT05656248 ↗ “Cytarabine 150mg/m\^2 q12h IVD d-5\~-2” NCT03629873 ↗ “High and intermediate dose Cytarabine” NCT06713837 ↗ “Dexamethasone, Cytarabine, Cisplatin” NCT01453504 ↗ “high dose cytarabine 2 mg/m2 q12h D2” NCT05244642 ↗ “Cytarabine 20 mg/m2 subcut days 1-5” NCT00740181 ↗ “Crizotinib, Cytarabine, Dacarbazine” NCT02788201 ↗ “Cytarabine 10mg/m²/12h, D1-D6 (IV)” NCT04216355 ↗ “Cytarabine 10mg/(m2.d) for 14 days” NCT03873311 ↗ “Cytarabine 10mg/m2, H, q12h, d1-7” NCT06329999 ↗ “cytarabine (total dose 900 mg/m2)” NCT04499573 ↗ “cytarabine 2 g/m²/day on day -8；” NCT03256071 ↗ “cytarabine 3g/m(2) i.v. Days 1-2” PMID 23242601 ↗ Dec 2012 “cytarabine 2 g/m² q12h on day -6” NCT07562568 ↗ “cytarabine 2 g/m² q12h on day -7” NCT07575412 ↗ “Cytarabine,Cytosine arabinoside” NCT06447090 ↗ “Day-10# Cytarabine 4g/m2/day CI” NCT05088226 ↗ “Drug: cytarabine, intravenously” NCT06652685 ↗ “* Cytarabine 500mg/m2, IV, D2-4” NCT05245656 ↗ “Cytarabine (Ara-C) 10mg/m² q12h” NCT07437170 ↗ “Cytarabine 2-3g／ｍ２, q12h, d2-3” NCT04134247 ↗ “Cytarabine,100 mg, IV, q12h/d.” NCT04541277 ↗ “dd 1-2: cytarabine twice a day” NCT01516593 ↗ “Fludarabine, cytarabine, G-CSF” NCT00559221 ↗ “Cytarabine :10mg/m2,q12h,d3-16” NCT04446130 ↗ “C: Cytarabine(15mg Q12h) d3-9” NCT04168138 ↗ “Cytarabine 500 mg/m2, Day 2-4” NCT05249959 ↗ “fixed-dose AraC (Cytarabine)” NCT02717884 ↗ “Cytarabine 100 mg/m2，qd，d1-7” NCT06328179 ↗ “cytarabine(30mg/m2, q1-3w)” NCT06230055 ↗ “Cytarabine 2000mg/m2 D1-5” NCT02431403 ↗ “Daunorubicin, Cytarabine” NCT03257241 ↗ “Cytarabine 2 g/m2, D5” NCT01300156 ↗ “Cytarabine: 1g/m2/d” NCT05583175 ↗ “Cytarabine (Ara-c)” NCT01513603 ↗ “cytarabine(Ara-C)” NCT06858618 ↗ “Drug: Cytarabine” NCT03206671 ↗ “Drug: Cytarabine” NCT02553460 ↗ “* Cytarabine” NCT00801580 ↗ “Cytarabine” NCT06529250 ↗ “Cytarabine” NCT00844298 ↗ “Cytarabine” NCT03837873 ↗ “Cytarabine” NCT02665065 ↗ “Cytarabine” NCT03793478 ↗ |
| Known as | 1-beta-d-arabinofuranosylcytosine | “A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease.” PMID 16278404 ↗ Nov 2005 |
| Known as | Alexan | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | Alexan 100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | Ara-C | “The goal of this clinical research study is to find the highest tolerable dose of Azacytidine (5-azacytidine) combined with cytosine arabinoside (ara-C) for the treatment of...” NCT00569010 ↗185“This is a single-arm, open label phase II trial of the investigational agent, Ara-C (cytarabine), in patients diagnosed with hormone refractory prostate cancer whose disease...” NCT00480090 ↗ “BACKGROUND: The combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested to be safe and effective for adult acute promyelocytic leukaemia...” PMID 29615003 ↗ Apr 2018 “Several phase II studies have suggested that cytarabine (AraC) was not required in the treatment of newly diagnosed acute promyelocytic leukemia (APL) patients receiving...” PMID 17116939 ↗ Nov 2006 “This has also been the basis for successful application and granting of Orphan-Drug designation for cytarabine (Ara-C) liposome injection (trade name: DepoCyt) for the...” NCT01044966 ↗ “Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With...” NCT00180167 ↗ “Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on...” NCT00022490 ↗ “Patients receive high-dose cytarabine (ARA-C) IV twice daily on days 1-10; daunorubicin IV over 6 hours on days 1, 3, and 5; etoposide IV over 4 hours on days 1-5; and...” NCT00070174 ↗ “The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and...” NCT06468267 ↗ “Induction chemotherapy consisted fludarabine and cytarabine (ARAC) as a 24-hr CI without idarubicin (C-FLAG), which was compared with the results of C-FLAG with idarubicin...” PMID 25891993 ↗ May 2015 “During all 3 courses of the CODOX-M regimen, patients receive CNS prophylaxis comprising cytarabine (ARA-C) intrathecally (IT) on days 1 and 3, MTX IT on day 15, and oral CF...” NCT00040690 ↗ “Intermediate-dose cytosine arabinoside (AraC), 1.6 g/m2 plus filgrastim, has been shown to produce very high efficacy as a first or second-line mobilization regimen in patients...” NCT02722733 ↗ “ML-DS blast cells ex vivo have increased sensitivity to cytarabine (araC) and daunorubicin, suggesting that optimizing drug dosing may improve outcomes while reducing toxicity.” PMID 28389462 ↗ Apr 2017 “The second goal of this clinical research study is to evaluate the safety and toxicity of the combination of BP1001 and concurrent low-dose ara-C (LDAC) in patients with AML.” NCT01159028 ↗ “Patients with meningeal or bone marrow disease will receive radiation and intrathecal cytarabine (ARA-C) while those without will receive ARA-C without radiation.” NCT00000703 ↗ “Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin.” NCT04342936 ↗ “Cytarabine (AraC) is a commercially available chemotherapy drug that is active against leukemia and used routinely when the disease is first diagnosed.” NCT00655395 ↗ “A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease.” PMID 16278404 ↗ Nov 2005 “R-HDS : Rituximab supplemented high-dose (Cyclophosphamide,Ara-C, Methotrexate, Etoposide, Cis-Platin) sequential chemotherapy with autografting.” NCT00355199 ↗ “Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran” NCT00574509 ↗ “HMA: Decitabine was administered at 20mg/m2/day for five consecutive days or Ara-C was administered at 75mg/m2/day for seven consecutive days.” NCT03662087 ↗ “FA+TBI+CY+VP-16: Flu: 35mg/m2/d: -10\~-6d; AraC: 1g/m2/d, -10d\~-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d” NCT01457040 ↗ “A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (CYTARABINE) in Elderly Patients With AML or High-Risk MDS” NCT00516828 ↗ “Resistant patients will receive a second induction with fludarabine, Ara-C, G-Colony-Stimulating Factor (G-CSF) and idarubicin (FLAG-IDA).” NCT04179929 ↗ “Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan.” NCT00281879 ↗ “FLAG consists of daily infusions of Fludarabine (30mg/m2/day over 30 minutes) and Ara-C (2g/m2/day over 4 hours) for 5 days” NCT05780879 ↗ “In this prospective study, we combine clofarabine and cytarabine (Ara-C) with the topoisomerase II inhibitor mitoxantrone.” NCT02686593 ↗ “Patients receive cytarabine (ARA-C) IV continuously on days 1 and 2 and then IV over 30 minutes every 12 hours on days 3-8” NCT00002517 ↗ “cytarabine (ARA-C) IV over 3 hours beginning 3 days after completion of MTX infusion and continuing daily for 2 days.” NCT00003632 ↗ “Patients with disease progression and no anti-IFN antibody also receive cytarabine (ARA-C) SC for 15 days a months.” NCT00002771 ↗ “Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection” NCT03969420 ↗ “TmBU conditioning regimen（TT 7mg/kg -8\~-7d; Ara-C 2g/m2/d -6d; CDA 5 mg/m2/d -6d; Bu 3.2 mg/kg/d from -5 to -3d）” NCT06816134 ↗ “granulocyte colony-stimulating factor (G-CSF) combined with low-dose cytarabine (Ara-C) and aclacinomycin (ACR)” NCT04168138 ↗ “high-dose BEAM (carmustine, etoposide, cytarabine, \[Ara-C, cytosine arabinoside\] and melphalan) chemotherapy” NCT01468311 ↗ “Cytarabine (AraC): ≥6g/m² per cycle (e.g., 1-2g/m², every 12 hours on days 1-3), administered intravenously.” NCT07672262 ↗ “triple intrathecal therapy (TIT) comprising MTX, cytarabine (ARA-C), and hydrocortisone on days 12 and 25.” NCT00003728 ↗ “B - Carmustine (BCNU) E - Etoposide. A - Cytarabine (Ara-C, cytosine arabinoside) M - Melphalan” NCT00571493 ↗ “For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).” NCT02676856 ↗ “C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8” NCT02520011 ↗ “ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)” NCT01500161 ↗ “Cytarabine (ARAC): 60 mg / m 2 iV in 1 hour 16 to 19, 23 to 26. (8 total doses).” NCT01366898 ↗ “DepoCyt is a new slow-release form of the cancer drug called ara-C (cytarabine).” NCT00029523 ↗ “Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2” NCT03187210 ↗ “cytarabine( Ara-C) 1500mg/m2(\<60 year old) ; 1000mg/m2(\>60 year old) IV q12h” NCT03453255 ↗ “MTX 12mg+Ara-C 50mg+Dex 5mg was injected into the CSF cytology-positive sheath” NCT04831658 ↗ “consisting of cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9” NCT03793517 ↗ “cytarabine (ARA-C) IV over 30 minutes on days 1-4, 8-11, 15-18, and 22-25.” NCT00002514 ↗ “Intermediate-dose cytosine arabinoside (AraC), 1.6 g/m2 plus filgrastim” NCT01908621 ↗ “Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.” NCT00927498 ↗ “Cytarabine (Ara-C): 75-100 mg/m\^2 every 12 hours from day 1 to day 7;” NCT06928376 ↗ “Other Names: Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride” NCT02809092 ↗ “Cytarabine (Ara-c) 100mg/㎡/day, days 3-7 (given as a 24-hour infusion)” NCT05893472 ↗ “Cytarabine (Ara-C): 75-100 mg/m\^2 every 12 hours from day 1 to day 7” NCT07514936 ↗ “intravenous cytosine arabinoside (Ara-C) 2 g/m2 twice daily on day -7” NCT06673459 ↗ “low-dose cytarabine (ARA-C) SC once daily for 10-15 days each month” NCT00025402 ↗ “cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9” NCT03799224 ↗ “Cytarabine (Ara-C): 1 g/m² IV q12h (Days 2-3; total 4 doses).” NCT07059156 ↗ “R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)” NCT02858258 ↗ “VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)” NCT01083342 ↗ “Cytarabine: (Ara-c 100mg/㎡/d, day 1-4; 1g/㎡ /q12h, day 5-7)” NCT06529250 ↗ “Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT” NCT01679860 ↗ “Cytarabine (Ara-C) 100 mg/m2/day CI/IV (x 5 days) day 2-6” NCT00187161 ↗ “cytarabine (ARA-C) on days 38-41, 45-48, 52-55 and 59-62” NCT01117441 ↗ “ARA-C: 1000 mg/m2 i.v., in 3 hours, days 14-15 and 42-43” NCT00526175 ↗ “cytarabine (Ara-C) which results in complete remission” NCT03257241 ↗ “Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3” NCT05966233 ↗ “Interferon-a (IFN-a) Combined With Cytarabine (Ara-C)” NCT00006343 ↗ “Ara-C (100 mg/m2/d by continuous IV infusion 7 days)” NCT00925873 ↗ “Haploidentical transplantation: AraC 2g/m2 d-10\~d-9” NCT05528354 ↗ “cytarabine (ARA-C) IV over 1 hour or subcutaneously” NCT00002531 ↗ “low-dose cytarabine (ara-C) and aclarubicin (ACR)” NCT05382390 ↗ “cytarabine (ARA-C) IV over 1 hour every 12 hours” NCT00006455 ↗ “Cytarabine (AraC) is administered intrathecally” NCT00003061 ↗ “AraC every 12 hours for four days (dd -5 to -2)” NCT01516593 ↗ “Cytosine arabinoside(Ara-C) 100 mg/m2/d, d1-7” NCT06447090 ↗ “Cytarabine \* (ARA-C) 1-2g/m2 q12H D2-3 iv” NCT05347641 ↗ “Cytosine Arabinoside (Cytarabine; Ara-C)” NCT00001048 ↗ “cytarabine (Ara-C) (4 g/m2/day, days -9)” NCT06984536 ↗ “Cytarabine (Ara-C, cytosine arabinoside)” NCT00572013 ↗ “Ara-C 1000mg/m2/q12h, IVGTT, D-3 to D-2” NCT05577611 ↗ “IDR + CY + ARA-C + ASP + 6MP + DXM + IT” NCT02067143 ↗ “cytarabine (ARA-C) IV over 30 minutes” NCT00550992 ↗ “Ara-C 400 mg/m2 from day -5 to day -2” NCT01296256 ↗ “Ara-C 300 mg/m2/dose Days 22, 25, 29” NCT00187057 ↗ “Ara-C (cytarabine) 300 mg/m2 IV push” NCT00187005 ↗ “Methotrexate and ara-C (cytarabine).” NCT00968253 ↗ “IT Cytarabine, IT ARA-C, NSC-63878” NCT00002471 ↗ “Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2” NCT05814718 ↗ “high dose Ara-C \[2 g/m2 IV, D5\]” NCT04378647 ↗ “cytarabine (ARA-C) in weeks 6-9” NCT00430118 ↗ “cytarabine (ARA-C) in weeks 6-9” NCT00613457 ↗ “Cytarabine (Ara-C) 10mg/m² q12h” NCT07437170 ↗ “Ara-C 10mg/m2, ih, q12h × 14d” NCT05918198 ↗ “Ara-C 4g/m2.d ，ivgtt，d-10- -9” NCT05814731 ↗ “cytosine arabinoside (ara-C)” NCT00136448 ↗ “high dose cytarabine (Ara-C)” NCT00002926 ↗ “Cytosine arabinoside [Ara-C]” NCT02072811 ↗ “ARA-C Cytarabine, NSC-63878” NCT00002549 ↗ “ARA-C Cytarabine, NSC-63878” NCT00002565 ↗ “ARA-C Cytarabine, NSC-63878” NCT00002691 ↗ “ARA-C Cytarabine, NSC-63878” NCT00002757 ↗ “Ara-C 2×2g/m2 q12h D2, I.V.” NCT06255704 ↗ “Ara-C 2×2g/m2 q12h D2, I.V.” NCT04736914 ↗ “Drug: Cytarabine (Ara-C)” NCT07007312 ↗ “Drug: Cytarabine (Ara-C)” NCT07078591 ↗ “Ara-C 100mg IT on day 9” NCT01184885 ↗ “Cytarabine (Ara-C)” NCT00004263 ↗ “cytarabine (ARA-C)” NCT00002701 ↗ “ARA-C (cytarabine)” NCT00801580 ↗ “Cytarabine (Ara-C)” NCT06742463 ↗ “Cytarabine (Ara-C)” NCT07059975 ↗ “Cytarabine (Ara-C)” NCT07643103 ↗ “Cytarabine (Ara-C)” NCT07060001 ↗ “cytarabine (ARA-C)” NCT00333840 ↗ “Cytarabine (Ara-C)” NCT07187193 ↗ “Cytarabine (Ara-C)” NCT07686107 ↗ “IT Ara-C on days 1” NCT05827549 ↗ “ARA-C Cytarabine” NCT00002674 ↗ “Cytarabine ARA-C” NCT00556127 ↗ “ARA- C: 30 mg” NCT02036489 ↗ “Ara-C” NCT02488408 ↗ |
| Known as | Ara-Cytarabine | “Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7” NCT06345365 ↗ |
| Known as | Ara-cytidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | Arabinocytosine | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | arabinoside | “Drug:arabinoside 2-3g/m2,q12h, d2-3, IV, used in cycle 1,3,5” NCT02042690 ↗ |
| Known as | ARABINOSYL-CYTOSINE | “ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5” NCT00909168 ↗ |
| Known as | aracytin | “L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)” NCT04475731 ↗1“* Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)” NCT02371161 ↗ |
| Known as | Aracytine | “Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle...” NCT01389427 ↗ |
| Known as | Citarabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | citarabine | “Chemotherapy is based upon regimes with well known effectiveness in Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide,...” NCT03500133 ↗1“1. cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)” NCT04184505 ↗ |
| Known as | CLAG Regimen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00955916 ↗ |
| Known as | Cytarabine (A) | “Cytarabine (A)” NCT01858922 ↗ |
| Known as | Cytarabine (ara-C) | “Cytarabine (ara-C)” NCT06325748 ↗1“Cytarabine (Ara-c)” NCT01513603 ↗ |
| Known as | Cytarabine (Cytarabine hydrochloride) | “Cytarabine (Cytarabine hydrochloride)” NCT05362942 ↗ |
| Known as | Cytarabine arabinoside | “FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen” NCT02013167 ↗ |
| Known as | Cytarabine component of vyxeos | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | Cytarabine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | Cytarabine Hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04220684 ↗ |
| Known as | Cytarabine Injection | “Drug: Cytarabine Injection” NCT03569995 ↗ |
| Known as | cytarabine liposome | “cytarabine liposome(50mg, q1-3w)” NCT06230055 ↗ |
| Known as | Cytarabinoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | Cytarabinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | cytarbine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00187083 ↗ |
| Known as | Cytosar | “Other Names: Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride” NCT02809092 ↗ |
| Known as | Cytosar-u | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | cytosine arabinoside | “The goal of this clinical research study is to find the highest tolerable dose of Azacytidine (5-azacytidine) combined with cytosine arabinoside (ara-C) for the treatment of...” NCT00569010 ↗39“This prospective interventional trial aims to test the efficacy and safety of the combination of methotrexate and cytosine arabinoside in adult LCH patients.” PMID 32423455 ↗ May 2020 “Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran” NCT00574509 ↗ “Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia” NCT00086099 ↗ “Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).” NCT06578247 ↗ “Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin).” NCT06841952 ↗ “high-dose BEAM (carmustine, etoposide, cytarabine, \[Ara-C, cytosine arabinoside\] and melphalan) chemotherapy” NCT01468311 ↗ “ESHAP (etoposide, methylprednisolone, cisplatin, cytosine arabinoside) chemotherapy was invented in 1994.” NCT00930605 ↗ “Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5” NCT00791947 ↗ “B - Carmustine (BCNU) E - Etoposide. A - Cytarabine (Ara-C, cytosine arabinoside) M - Melphalan” NCT00571493 ↗ “after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide” NCT01947322 ↗ “Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 10 inclusive” NCT02272478 ↗ “Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients” NCT00952588 ↗ “combination with cytarabine (cytosine arabinoside, Ara-C) or decitabine” NCT02488408 ↗ “intravenous cytosine arabinoside (Ara-C) 2 g/m2 twice daily on day -7” NCT06673459 ↗ “Cytosine Arabinoside (Cytarabine; Ara-C)” NCT00001048 ↗ “Cytarabine (Ara-C, cytosine arabinoside)” NCT00572013 ↗ “Drug: cytosine arabinoside Given IV” NCT05922384 ↗ “Ara-C (cytosine arabinoside)” NCT00303290 ↗ “Cytosine arabinoside [Ara-C]” NCT02072811 ↗ “Cytosine arabinoside” NCT02277847 ↗ “Cytosine Arabinoside” NCT00592111 ↗ |
| Known as | cytosine arabinoside (ara-C) | “cytosine arabinoside (ara-C)” NCT02670707 ↗ |
| Known as | Cytosine arabinoside hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | Cytosine arabinosine hydrochloride | “Other Names: Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride” NCT02809092 ↗ |
| Known as | DepoCyt | “Other Names: Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride” NCT02809092 ↗ |
| Known as | DEPOCYT (Cytarabine Liposome Injection) | “DEPOCYT® (Cytarabine Liposome Injection)” NCT01859819 ↗ |
| Known as | DepoCyte | “The objective of the study is
1. To investigate the efficacy and safety of a high-dose methotrexate-based induction polychemotherapy regimen combined with Rituximab and...” NCT01458730 ↗4“Liposomal cytarabine (DepoCyte) is a new formulation of the drug cytarabine, a drug commonly used in the treatment of ALL.” NCT01593488 ↗ “intrathecal liposomal cytarabine (DepoCyte®)” NCT00854867 ↗ |
| Known as | Depofoam encapsulated cytarabine | “liposomal cytarabine (Depofoam encapsulated cytarabine; DTC 101)” NCT00003073 ↗ |
| Known as | DTC101 | “liposomal cytarabine (Depofoam encapsulated cytarabine; DTC 101)” NCT00003073 ↗1“intrathecal sustained release cytarabine (DTC101)” NCT00002704 ↗ |
| Known as | HiDAC | “Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)” NCT01246752 ↗1“high-dose cytarabine (HIDAC)” NCT02633137 ↗ |
| Known as | IDAC | “Intermediate-dose cytarabine (IDAC)” NCT02577406 ↗ |
| Known as | IT ARA-C | “Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, AlBM; with, as indicated, Intrathecal Cytarabine, IT ARA-C, NSC-63878.” NCT00002502 ↗ |
| Known as | LDAC | “The second goal of this clinical research study is to evaluate the safety and toxicity of the combination of BP1001 and concurrent low-dose ara-C (LDAC) in patients with AML.” NCT01159028 ↗7“Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.” NCT00804856 ↗ “Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients” NCT00952588 ↗ “Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.” NCT02038777 ↗ “Low-dose subcutaneous cytarabine (LDAC) 20 mg/m2/daily SC, days 1 to 10” NCT04687761 ↗ “glasdegib plus low-dose cytarabine (LDAC)” PMID 30555165 ↗ Dec 2018 “LDAC (low dose cytosine arabinoside)” NCT00926731 ↗ “Low-dose cytarabine (LDAC)” NCT02577406 ↗ |
| Known as | liposomal cytarabine | “Liposomal cytarabine (DepoCyte) is a new formulation of the drug cytarabine, a drug commonly used in the treatment of ALL.” NCT01593488 ↗3“liposomal cytarabine (Depofoam encapsulated cytarabine; DTC 101)” NCT00003073 ↗ “Drug: liposomal cytarabine” NCT00002704 ↗ |
| Known as | Liposomal daunorubicin and cytarabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04801797 ↗ |
| Known as | LoDAC | “Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) injection for 10 days.” NCT05876832 ↗3“Low-dose or high-dose cytarabine (LoDAC) will be administered by intravenous (IV) injections.” NCT05100303 ↗ “Drug: LoDAC (Low Dose Cytarabine)” NCT02421939 ↗ “Low-dose cytarabine (LoDAC)” NCT04716114 ↗ |
| Known as | Low Dose Cytarabine | “Drug: LoDAC (Low Dose Cytarabine)” NCT02421939 ↗ |
| Known as | NSC-287459 | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | NSC-63878 | “Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, AlBM; with, as indicated, Intrathecal Cytarabine, IT ARA-C, NSC-63878.” NCT00002502 ↗4“Intrathecal Cytarabine, IT ARA-C, NSC-63878” NCT00002499 ↗ “IT Cytarabine, IT ARA-C, NSC-63878” NCT00002471 ↗ “ARA-C Cytarabine, NSC-63878” NCT00002565 ↗ “ARA-C Cytarabine, NSC-63878” NCT00002691 ↗ |
| Known as | Spongocytidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | Tarabine pfs | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | U 19920a | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Known as | U-19,920 | ChEMBL registry synonym — accepted as the source's own label CHEMBL803 ↗ |
| Action | Inhibit | “Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.” NCT00005585 ↗ |
| Modality | Small molecule | “Pyrimidine nucleoside analogue, an antineoplastic agent.” NCT02724163 ↗ |
| Route | Intrathecal | “intrathecal cytarabine (ARA-C)” NCT00000703 ↗ |